Enterprise Value
-32.62M
Cash
119.1M
Avg Qtr Burn
-19.58M
Short % of Float
9.71%
Insider Ownership
2.78%
Institutional Own.
95.83%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATI-1777 (JAK 1/3 inhibitor) Details Atopic dermatitis, Skin disease/disorder | Phase 2b Update | |
Zunsemetinib (ATI-450) (MK2 inhibitor) Details Psoriatic arthritis | Phase 2a Update | |
ATI-2138 (ITK/JAK3 inhibitor) Details Autoimmune disease, Ulcerative colitis | Phase 2a Initiation | |
ATI-2231 (MK2 inhibitor) Details Solid tumor/s, Metastatic breast cancer, Pancreatic cancer, Cancer | Phase 1a Update | |
Zunsemetinib (ATI-450) (MK2 inhibitor) Details Hidradenitis suppurativa | Failed Discontinued | |
Zunsemetinib (ATI-450) Details COVID-19 | Failed Discontinued | |
Zunsemetinib (ATI-450) Details Rheumatoid arthritis | Failed Discontinued |